Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

Clinical trial NCT00115219 · COMPLETED

Trial details

NCT number: NCT00115219
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Rheumatoid Arthritis

Start date: 2005-05-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.